Ozagrel Sodium

Drug #2286

Ozagrel is an antiplatelet agent working as a thromboxane A2 synthesis inhibitor.

← Previous drug Next drug →

Primary Characteristics

It is of Synthetic origin.

It is classified in Antiplatelet Agent pharmacological group.

Molecular Weight: 500 · Solubility in Water: freely · Non-proprietary name: Lacosamide.

Pharmacokinetics

None recorded.

Indications

Ozagrel Sodium is primarily indicated in conditions like Cerebral infarction.

Contraindications

None recorded.

Dosage

Ozagrel Sodium's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
120 mg	120 mg	Every 2h	IV	solute in 500ml normal saline or 5% glucose solution, intravenous infusion, treatment duration is 2 weeks.
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

1 interaction

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Ozagrel Sodium in overdosage may give rise to further complications which include hemorrhagic cerebral infraction, extradural hemorrhage, encephalic hemorrhage, gastrointestinal hemmorahe, subcutaneous hemorrhag.

Ozagrel Sodium is known to cause more or less tolerable side effects which are usually transient. These include Abdominal distension, Anorexia , Diarrhea, Fever, Headache, Hypotension, Nausea and vomiting, Skin rashes, Supraventricular arrythemia, Urticaria.

Warnings / Precautions

Avoid mixing use of this drug and solution containing calcium (Green's solution) in case there will be white turbidity.Pregnant women should be administered with Ozagrel Sodium for Injection with extreme care. the elder should be administered with Ozagrel Sodium for Injection with extreme care because of the low biological activity .

Interference in Pathology

Ozagrel Sodium may interfere in the diagnosis of BUN increased, GOT increased, GPT incresed.

Available Brands

None recorded.

Storage Conditions

Ozagrel Sodium should be stored IV.

Drug Classification

1.10.2 — Anticoagulants/Platelet deaggregators